Medical Breakthrough: FDA Grants Emergency Approval for “NeuroRevive,” First Drug Proven to Reverse Early Alzheimer’s
In a decision that offers a glimmer of hope to millions of families worldwide, the U.S. Food and Drug Administration (FDA) late Saturday granted accelerated approval to NeuroRevive (anexolimab-gx), the first pharmaceutical treatment clinically proven to not just slow, but partially reverse cognitive decline in early-stage Alzheimer’s patients.
